Phio Pharmaceuticals Corp. reports developments as a clinical-stage siRNA biopharmaceutical company advancing its proprietary INTASYL® gene-silencing technology for immuno-oncology. Company updates center on PH-762, an INTASYL compound designed to silence the PD-1 gene and evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Recurring news themes include PH-762 clinical results, safety and pathology data, nonclinical toxicology work, cGMP clinical-supply manufacturing, regulatory-development steps, financial results, equity financing activity and investor presentations. Coverage also reflects the company's use of self-delivering RNAi technology intended to enhance immune-cell activity against tumor cells without specialized formulation or delivery systems.
Phio Pharmaceuticals (NASDAQ: PHIO) reported a key milestone for its lead candidate PH-762. Nitto Denko Avecia has begun the first commercial-scale cGMP production of PH-762 drug substance under a services agreement signed in June 2025.
The new supply is intended to support an upcoming clinical trial in the next development phase of Phio's intratumoral program. Phio also recently completed a Phase 1b dose-escalation study of PH-762 for cutaneous carcinomas.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharma company, will participate in the Life Sciences Investor Forum on June 24-25, 2026.
CEO Robert Bitterman will present the INTASYL gene-silencing platform and lead candidate PH-762 for cutaneous carcinomas, followed by live Q&A and one-on-one meetings.
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in Renmark Financial Communications’ Live Virtual Non-Deal Roadshow Series on Thursday, May 28, 2026 at 12 PM EDT. CEO and Chairman Robert Bitterman will present the company’s INTASYL siRNA gene silencing platform and lead candidate PH-762 for cutaneous carcinomas, followed by a live Q&A.
PH-762, which silences the PD-1 gene, is in a Phase 1b trial (NCT# 06014086) for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma as a potential non-surgical skin cancer treatment.
Phio Pharmaceuticals (NASDAQ: PHIO) will host a live virtual fireside chat with Force Family Office on May 19, 2026 at 4 PM EDT, focused on innovations in skin cancer treatment and prevention.
Recent highlights include Phase 1b data for PH-762 showing no dose-limiting toxicities or serious adverse events among 22 treated patients, a reported ~65% pathological response rate in cSCC (including 6 of 7 responders in the highest-dose cohort), targeted FDA engagement in Q2 2026, and cash projected to fund operations into the first half of 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) reported Q1 2026 results and a business update on May 7, 2026. The company completed its Phase 1b dose‑escalation trial of PH‑762 with favorable safety/pathology signals and targets an FDA submission in Q2 2026 to define next clinical steps.
Key financials: $17M cash at March 31, 2026; net loss of $4.0M for Q1 2026; R&D spend rose 215% YoY. Capital actions include ~$23.7M net proceeds in 2025 and an ATM for up to $6.36M.
Phio Pharmaceuticals (NASDAQ: PHIO) will present in a live Virtual Non-Deal Roadshow on April 29, 2026 at 12 PM EDT. CEO Robert Bitterman will overview the INTASYL siRNA platform, discuss PH-762 clinical progress, and host a live Q&A.
Phio reported 22 patients completed Phase 1b across five dose cohorts with no dose-limiting toxicities or serious adverse events; pathological response in cSCC was ~65% overall and 85% (6 of 7) in the highest-dose cohort.
Phio Pharmaceuticals (NASDAQ: PHIO) announced a virtual fireside chat on April 15, 2026 with Force Family Office featuring CEO Robert Bitterman and Dr. R. Todd Plott to discuss INTASYL siRNA program and PH-762, an intratumoral PD-1–silencing candidate for skin cancers.
Phio reported that 22 patients completed Phase 1b treatment across five dose cohorts with no dose-limiting toxicities or serious adverse events, ~65% pathological response in cSCC overall and 85% response (6 of 7) at the highest dose. FDA engagement on next-stage development is targeted for Q2 2026. Cash is projected to sustain operations into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the Centri Capital Conference on April 14, 2026 at Nasdaq Marketsite in New York City. CEO and Chairman Robert Bitterman will discuss recent clinical progress and the INTASYL PH-762 program in immuno-oncology.
The presentation is scheduled for 10:30 a.m. ET and will be available via virtual webcast; registration is through the conference registration link.
Phio Pharmaceuticals (NASDAQ: PHIO) entered a cGMP U.S. drug product manufacturing services agreement to supply its lead siRNA candidate PH-762 for clinical and potential commercial use. The move supports next-stage trials for intratumoral treatment of cutaneous carcinomas and secures domestic capacity for clinical supply.
Phio reported Phase 1b data: 22 patients treated with no dose-limiting toxicities, ~65% pathological response in cSCC across cohorts, and 85% response in the highest-dose cohort. FDA engagement is targeted for Q2 2026; cash runway is projected into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) will present Phase 1b clinical results for PH-762 at the American Academy of Dermatology Late-Breaking Research Session on March 28, 2026 at 3:00 PM MDT in Denver. The presentation reports 22 patients treated across five dose cohorts, no dose-limiting toxicities or serious adverse events, ~65% pathological response in cSCC overall and 85% response in the highest-dose cohort. FDA engagement for next-stage development is targeted for Q2 2026; cash runway is projected into H1 2027.